Celltrion submits for subcutaneous infliximab in inflammatory bowel disease

Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.“This BLA submission marks a significant milestone for Celltrion and we are working with the FDA to bring this innovative treatment to the U.S. market,” Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, said in the release. “We are committed to furthering the advancement of innovative treatments that provide improvements to clinical outcomes and drugRead More

Generated by Feedzy